Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates

分组1 - Janux Therapeutics reported a quarterly loss of $0.39 per share, better than the Zacks Consensus Estimate of a loss of $0.60, and improved from a loss of $0.51 per share a year ago, resulting in an earnings surprise of +35.00% [1] - The company posted revenues of $10 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 28.01%, compared to revenues of $0.44 million in the same quarter last year [2] - Janux Therapeutics shares have declined approximately 48.6% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] 分组2 - The earnings outlook for Janux Therapeutics is mixed, with the current consensus EPS estimate for the coming quarter at -$0.74 on revenues of $1.25 million, and -$2.37 on revenues of $8.13 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Janux Therapeutics belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]